The novel desmopressin analogue [V4Q5]dDAVP inhibits angiogenesis, tumour growth and metastases in vasopressin type 2 receptor-expressing breast cancer models

Garona,Juan; Pifano,Marina; Orlando,Ulises  D.; Pastrian,Maria  B.; Iannucci,Nancy  B.; Ortega,Hugo  H.; Podesta,Ernesto  J.; Gomez,Daniel  E.; Ripoll,Giselle V.; Alonso,Daniel F.

doi:10.3892/ijo.2015.2952

The novel desmopressin analogue [V4Q5]dDAVP inhibits angiogenesis, tumour growth and metastases in vasopressin type 2 receptor-expressing breast cancer models

Authors:
- Juan Garona
- Marina Pifano
- Ulises D. Orlando
- Maria B. Pastrian
- Nancy B. Iannucci
- Hugo H. Ortega
- Ernesto J. Podesta
- Daniel E. Gomez
- Giselle V. Ripoll
- Daniel F. Alonso
View Affiliations

Affiliations: Laboratory of Molecular Oncology, National University of Quilmes, Bernal, B1876BXD, Buenos Aires, Argentina, Biomedical Research Institute (INBIOMED), Department of Human Biochemistry, School of Medicine, University of Buenos Aires, Buenos Aires, Argentina, School of Pharmacy and Biochemistry, University of Buenos Aires, Buenos Aires, Argentina, Institute of Veterinary Sciences (ICIVET-CONICET), National University of Litoral, Esperanza, Santa Fe, Argentina
Published online on: April 3, 2015 https://doi.org/10.3892/ijo.2015.2952
Pages: 2335-2345
Copyright: © Garona et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 3.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Desmopressin (dDAVP) is a safe haemostatic agent with previously reported antitumour activity. It acts as a selective agonist for the V2 vasopressin membrane receptor (V2r) present on tumour cells and microvasculature. The purpose of this study was to evaluate the novel peptide derivative [V4Q5]dDAVP in V2r-expressing preclinical mouse models of breast cancer. We assessed antitumour effects of [V4Q5]dDAVP using human MCF-7 and MDA‑MB‑231 breast carcinoma cells, as well as the highly metastatic mouse F3II cell line. Effect on in vitro cancer cell growth was evaluated by cell proliferation and clonogenic assays. Cell cycle distribution was analysed by flow cytometry. In order to study the effect of intravenously administered [V4Q5]dDAVP on tumour growth and angiogenesis, breast cancer xenografts were generated in athymic mice. F3II cells were injected into syngeneic mice to evaluate the effect of [V4Q5]dDAVP on spontaneous and experimental metastatic spread. In vitro cytostatic effects of [V4Q5]dDAVP against breast cancer cells were greater than those of dDAVP, and associated with V2r-activated signal transduction and partial cell cycle arrest. In MDA‑MB‑231 xenografts, [V4Q5]dDAVP (0.3 µg/kg, thrice a week) reduced tumour growth and angiogenesis. Treatment of F3II mammary tumour-bearing immunocompetent mice resulted in complete inhibition of metastatic progression. [V4Q5]dDAVP also displayed greater antimetastatic efficacy than dDAVP on experimental lung colonisation by F3II cells. The novel analogue was well tolerated in preliminary acute toxicology studies, at doses ≥300-fold above that required for anti-angiogenic/antimetastatic effects. Our data establish the preclinical activity of [V4Q5]dDAVP in aggressive breast cancer, providing the rationale for further clinical trials.

View Figures

View References

1	Vande Walle J, Stockner M, Raes A and Nørgaard JP: Desmopressin 30 years in clinical use: A safety review. Curr Drug Saf. 2:232–238. 2007. View Article : Google Scholar
2	Manning M, Stoev S, Chini B, Durroux T, Mouillac B and Guillon G: Peptide and non-peptide agonists and antagonists for the vasopressin and oxytocin V1a, V1b, V2 and OT receptors: Research tools and potential therapeutic agents. Prog Brain Res. 170:473–512. 2008.PubMed/NCBI
3	Kaufmann JE and Vischer UM: Cellular mechanisms of the hemostatic effects of desmopressin (DDAVP). J Thromb Haemost. 1:682–689. 2003. View Article : Google Scholar : PubMed/NCBI
4	Mannucci PM: Desmopressin (DDAVP) in the treatment of bleeding disorders: The first 20 years. Blood. 90:2515–2521. 1997.PubMed/NCBI
5	Manning M, Misicka A, Olma A, Bankowski K, Stoev S, Chini B, Durroux T, Mouillac B, Corbani M and Guillon G: Oxytocin and vasopressin agonists and antagonists as research tools and potential therapeutics. J Neuroendocrinol. 24:609–628. 2012. View Article : Google Scholar : PubMed/NCBI
6	North WG, Fay MJ and Du J: MCF-7 breast cancer cells express normal forms of all vasopressin receptors plus an abnormal V2R. Peptides. 20:837–842. 1999. View Article : Google Scholar : PubMed/NCBI
7	Petit T, Davidson KK, Lawrence RA, von Hoff DD and Izbicka E: Neuropeptide receptor status in human tumor cell lines. Anticancer Drugs. 12:133–136. 2001. View Article : Google Scholar : PubMed/NCBI
8	Taylor AH, Ang VT, Jenkins JS, Silverlight JJ, Coombes RC and Luqmani YA: Interaction of vasopressin and oxytocin with human breast carcinoma cells. Cancer Res. 50:7882–7886. 1990.PubMed/NCBI
9	Alonso DF, Skilton G, Farías EF, Bal de Kier Joffé E and Gomez DE: Antimetastatic effect of desmopressin in a mouse mammary tumor model. Breast Cancer Res Treat. 57:271–275. 1999. View Article : Google Scholar
10	Garona J, Pifano M, Scursoni AM, Gomez DE, Alonso DF and Ripoll GV: Insight into the effect of the vasopressin analog desmopressin on lung colonization by mammary carcinoma cells in BALB/c mice. Anticancer Res. 34:4761–4765. 2014.PubMed/NCBI
11	Giron S, Tejera AM, Ripoll GV, Gomez DE and Alonso DF: Desmopressin inhibits lung and lymph node metastasis in a mouse mammary carcinoma model of surgical manipulation. J Surg Oncol. 81:38–44. 2002. View Article : Google Scholar : PubMed/NCBI
12	Hermo GA, Torres P, Ripoll GV, Scursoni AM, Gomez DE, Alonso DF and Gobello C: Perioperative desmopressin prolongs survival in surgically treated bitches with mammary gland tumours: A pilot study. Vet J. 178:103–108. 2008. View Article : Google Scholar
13	Hermo GA, Turic E, Angelico D, Scursoni AM, Gomez DE, Gobello C and Alonso DF: Effect of adjuvant perioperative desmopressin in locally advanced canine mammary carcinoma and its relation to histologic grade. J Am Anim Hosp Assoc. 47:21–27. 2011. View Article : Google Scholar
14	Terraube V, Pendu R, Baruch D, Gebbink MF, Meyer D, Lenting PJ and Denis CV: Increased metastatic potential of tumor cells in von Willebrand factor-deficient mice. J Thromb Haemost. 4:519–526. 2006. View Article : Google Scholar : PubMed/NCBI
15	Ripoll GV, Garona J, Pifano M, Farina HG, Gomez DE and Alonso DF: Reduction of tumor angiogenesis induced by desmopressin in a breast cancer model. Breast Cancer Res Treat. 142:9–18. 2013. View Article : Google Scholar : PubMed/NCBI
16	Sakurai T and Kudo M: Signaling pathways governing tumor angiogenesis. Oncology. 81(Suppl 1): 24–29. 2011. View Article : Google Scholar
17	Westphal JR, Van’t Hullenaar R, Geurts-Moespot A, Sweep FC, Verheijen JH, Bussemakers MM, Askaa J, Clemmensen I, Eggermont AA, Ruiter DJ, et al: Angiostatin generation by human tumor cell lines: involvement of plasminogen activators. Int J Cancer. 86:760–767. 2000. View Article : Google Scholar : PubMed/NCBI
18	Alonso DF, Ripoll GV, Garona J, Iannucci NB and Gomez DE: Metastasis: Recent discoveries and novel perioperative treatment strategies with particular interest in the hemostatic compound desmopressin. Curr Pharm Biotechnol. 12:1974–1980. 2011. View Article : Google Scholar : PubMed/NCBI
19	Czaplewski C, Kaźmierkiewicz R and Ciarkowski J: Molecular modeling of the human vasopressin V2 receptor/agonist complex. J Comput Aided Mol Des. 12:275–287. 1998. View Article : Google Scholar : PubMed/NCBI
20	Czaplewski C, Kaźmierkiewicz R and Ciarkowski J: Molecular modelling of the vasopressin V2 receptor/antagonist interactions. Acta Biochim Pol. 45:19–26. 1998.PubMed/NCBI
21	Iannucci NB, Ripoll GV, Garona J, Cascone O, Ciccia GN, Gomez DE and Alonso DF: Antiproliferative effect of 1-deamino-8-D-arginine vasopressin analogs on human breast cancer cells. Future Med Chem. 3:1987–1993. 2011. View Article : Google Scholar : PubMed/NCBI
22	Pastrian MB, Guzmán F, Garona J, Pifano M, Ripoll GV, Cascone O, Ciccia GN, Albericio F, Gómez DE, Alonso DF, et al: Structure-activity relationship of 1-desamino-8-D-arginine vasopressin as an antiproliferative agent on human vasopressin V2 receptor-expressing cancer cells. Mol Med Rep. 9:2568–2572. 2014.PubMed/NCBI
23	Holliday DL and Speirs V: Choosing the right cell line for breast cancer research. Breast Cancer Res. 13:2152011. View Article : Google Scholar : PubMed/NCBI
24	Ripoll GV, Giron S, Krzymuski MJ, Hermo GA, Gomez DE and Alonso DF: Antitumor effects of desmopressin in combination with chemotherapeutic agents in a mouse model of breast cancer. Anticancer Res. 28A:2607–2611. 2008.
25	Cardama GA, Comin MJ, Hornos L, Gonzalez N, Defelipe L, Turjanski AG, Alonso DF, Gomez DE and Menna PL: Preclinical development of novel Rac1-GEF signaling inhibitors using a rational design approach in highly aggressive breast cancer cell lines. Anticancer Agents Med Chem. 14:840–851. 2014. View Article : Google Scholar :
26	Jones LW, Eves ND, Courneya KS, Chiu BK, Baracos VE, Hanson J, Johnson L and Mackey JR: Effects of exercise training on antitumor efficacy of doxorubicin in MDA-MB-231 breast cancer xenografts. Clin Cancer Res. 11:6695–6698. 2005. View Article : Google Scholar : PubMed/NCBI
27	Kaufmann JE, Oksche A, Wollheim CB, Günther G, Rosenthal W and Vischer UM: Vasopressin-induced von Willebrand factor secretion from endothelial cells involves V2 receptors and cAMP. J Clin Invest. 106:107–116. 2000. View Article : Google Scholar : PubMed/NCBI
28	Han SS, Cho CK, Lee YW and Yoo HS: Antimetastatic and immunomodulating effect of water extracts from various mushrooms. J Acupunct Meridian Stud. 2:218–227. 2009. View Article : Google Scholar
29	North WG, Pai S, Friedmann A, Yu X, Fay M and Memoli V: Vasopressin gene related products are markers of human breast cancer. Breast Cancer Res Treat. 34:229–235. 1995. View Article : Google Scholar : PubMed/NCBI
30	Keegan BP, Akerman BL, Péqueux C and North WG: Provasopressin expression by breast cancer cells: Implications for growth and novel treatment strategies. Breast Cancer Res Treat. 95:265–277. 2006. View Article : Google Scholar
31	Carie AE and Sebti SM: A chemical biology approach identifies a beta-2 adrenergic receptor agonist that causes human tumor regression by blocking the Raf-1/Mek-1/Erk1/2 pathway. Oncogene. 26:3777–3788. 2007. View Article : Google Scholar : PubMed/NCBI
32	Insel PA, Zhang L, Murray F, Yokouchi H and Zambon AC: Cyclic AMP is both a pro-apoptotic and anti-apoptotic second messenger. Acta Physiol (Oxf). 204:277–287. 2012. View Article : Google Scholar
33	Naviglio S, Di Gesto D, Romano M, Sorrentino A, Illiano F, Sorvillo L, Abbruzzese A, Marra M, Caraglia M, Chiosi E, et al: Leptin enhances growth inhibition by cAMP elevating agents through apoptosis of MDA-MB-231 breast cancer cells. Cancer Biol Ther. 8:1183–1190. 2009. View Article : Google Scholar : PubMed/NCBI
34	Castoria G, Migliaccio A, D’Amato L, Di Stasio R, Ciociola A, Lombardi M, Bilancio A, Di Domenico M, De Falco A and Auricchio F: Integrating signals between cAMP and MAPK pathways in breast cancer. Front Biosci. 13:1318–1327. 2008. View Article : Google Scholar
35	Gluz O, Liedtke C, Gottschalk N, Pusztai L, Nitz U and Harbeck N: Triple-negative breast cancer--current status and future directions. Ann Oncol. 20:1913–1927. 2009. View Article : Google Scholar : PubMed/NCBI
36	Bayraktar S and Glück S: Molecularly targeted therapies for metastatic triple-negative breast cancer. Breast Cancer Res Treat. 138:21–35. 2013. View Article : Google Scholar : PubMed/NCBI
37	Terrenato I, Arena V, Pizzamiglio S, Pennacchia I, Perracchio L, Buglioni S, Ercolani C, Sperati F, Costarelli L, Bonanno E, et al: External Quality Assessment (EQA) program for the preanalytical and analytical immunohistochemical determination of HER2 in breast cancer: An experience on a regional scale. J Exp Clin Cancer Res. 32:582013. View Article : Google Scholar : PubMed/NCBI
38	Gangloff A, Hsueh WA, Kesner AL, Kiesewetter DO, Pio BS, Pegram MD, Beryt M, Townsend A, Czernin J, Phelps ME, et al: Estimation of paclitaxel biodistribution and uptake in human-derived xenografts in vivo with (18)F-fluoropaclitaxel. J Nucl Med. 46:1866–1871. 2005.PubMed/NCBI
39	Ripoll G, Iannucci N, Giron S, Cascone O, Gomez D and Alonso D: Angiostatic activity of 1-Deamino-8-D-Arginine vasopressin and novel peptide analogues in breast cancer cells. Proc AACR Abst. 295:2008.
40	Huang J, Roth R, Heuser JE and Sadler JE: Integrin alpha(v) beta(3) on human endothelial cells binds von Willebrand factor strings under fluid shear stress. Blood. 113:1589–1597. 2009. View Article : Google Scholar :
41	Starke RD, Ferraro F, Paschalaki KE, Dryden NH, McKinnon TA, Sutton RE, Payne EM, Haskard DO, Hughes AD, Cutler DF, et al: Endothelial von Willebrand factor regulates angiogenesis. Blood. 117:1071–1080. 2011. View Article : Google Scholar :
42	Howe AK: Regulation of actin-based cell migration by cAMP/ PKA. Biochim Biophys Acta. 1692:159–174. 2004. View Article : Google Scholar : PubMed/NCBI
43	Howe AK, Baldor LC and Hogan BP: Spatial regulation of the cAMP-dependent protein kinase during chemotactic cell migration. Proc Natl Acad Sci USA. 102:14320–14325. 2005. View Article : Google Scholar : PubMed/NCBI
44	Kim S, Harris M and Varner JA: Regulation of integrin alpha vbeta 3-mediated endothelial cell migration and angiogenesis by integrin alpha5beta1 and protein kinase A. J Biol Chem. 275:33920–33928. 2000. View Article : Google Scholar : PubMed/NCBI
45	Terraube V, Marx I and Denis CV: Role of von Willebrand factor in tumor metastasis. Thromb Res. 120(Suppl 2): S64–S70. 2007. View Article : Google Scholar : PubMed/NCBI
46	Mochizuki S, Soejima K, Shimoda M, Abe H, Sasaki A, Okano HJ, Okano H and Okada Y: Effect of ADAM28 on carcinoma cell metastasis by cleavage of von Willebrand factor. J Natl Cancer Inst. 104:906–922. 2012. View Article : Google Scholar : PubMed/NCBI
47	Erdélyi LS, Balla A, Patócs A, Tóth M, Várnai P and Hunyady L: Altered agonist sensitivity of a mutant v2 receptor suggests a novel therapeutic strategy for nephrogenic diabetes insipidus. Mol Endocrinol. 28:634–643. 2014. View Article : Google Scholar : PubMed/NCBI
48	Liu H, Gaza-Bulseco G and Chumsae C: Glutamine deamidation of a recombinant monoclonal antibody. Rapid Commun Mass Spectrom. 22:4081–4088. 2008. View Article : Google Scholar : PubMed/NCBI
49	Robinson AB and Rudd CJ: Deamidation of glutaminyl and asparaginyl residues in peptides and proteins. Curr Top Cell Regul. 8:247–295. 1974.PubMed/NCBI
50	Lianos GD, Vlachos K, Zoras O, Katsios C, Cho WC and Roukos DH: Potential of antibody-drug conjugates and novel therapeutics in breast cancer management. Onco Targets Ther. 7:491–500. 2014.PubMed/NCBI
51	Bacic I, Druzijanic N, Karlo R, Skific I and Jagic S: Efficacy of IP6 inositol in the treatment of breast cancer patients receiving chemotherapy: Prospective, randomized, pilot clinical study. J Exp Clin Cancer Res. 29:122010. View Article : Google Scholar
52	Fabbrocini G, Cameli N, Romano MC, Mariano M, Panariello L, Bianca D and Monfrecola G: Chemotherapy and skin reactions. J Exp Clin Cancer Res. 31:502012. View Article : Google Scholar : PubMed/NCBI
53	Wang S, Noberini R, Stebbins JL, Das S, Zhang Z, Wu B, Mitra S, Billet S, Fernandez A, Bhowmick NA, et al: Targeted delivery of paclitaxel to EphA2-expressing cancer cells. Clin Cancer Res. 19:128–137. 2013. View Article : Google Scholar :